Drug intelligence / Profile preview

WBMP-3

Development stage: Preclinical
Lead developer: Welt Bio-Molecular Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

WBMP-3 is a first-in-class monoclonal antibody developed by Welt Bio-Molecular Pharmaceutical, currently in preclinical development for the treatment of B-cell malignancies, including Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). It specifically targets critical epitopes on the membrane IgM (mIgM) component of the B-cell Receptor Complex (BCRC). The mechanism of action involves binding to mIgM on malignant B cells, which triggers receptor internalization, inhibits cell growth, and induces apoptosis. WBMP-3 is part of a pipeline of antibodies (WBMP-1 through WBMP-4) aimed at hematological cancers, with WBMP-4 currently identified as the lead product in the series.

Targets

mIgM (Immunoglobulin heavy constant mu)

Beyond the preview

Go deeper on WBMP-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WBMP-3.

Explore the full profile